King Luther Capital Management Corp Cuts Stock Position in Enovis Co. (NYSE:ENOV)

King Luther Capital Management Corp decreased its holdings in Enovis Co. (NYSE:ENOV - Free Report) by 11.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 131,662 shares of the company's stock after selling 16,729 shares during the quarter. King Luther Capital Management Corp owned 0.23% of Enovis worth $5,777,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. State of New Jersey Common Pension Fund D boosted its holdings in Enovis by 15.4% in the third quarter. State of New Jersey Common Pension Fund D now owns 43,404 shares of the company's stock valued at $1,869,000 after purchasing an additional 5,801 shares during the period. Aigen Investment Management LP raised its position in Enovis by 5.1% in the 3rd quarter. Aigen Investment Management LP now owns 8,859 shares of the company's stock valued at $381,000 after purchasing an additional 430 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Enovis by 14.3% in the 3rd quarter. Victory Capital Management Inc. now owns 32,846 shares of the company's stock valued at $1,414,000 after buying an additional 4,099 shares during the period. Oppenheimer Asset Management Inc. grew its position in shares of Enovis by 19.8% during the third quarter. Oppenheimer Asset Management Inc. now owns 11,829 shares of the company's stock worth $509,000 after buying an additional 1,953 shares in the last quarter. Finally, Royce & Associates LP increased its stake in shares of Enovis by 16.8% during the third quarter. Royce & Associates LP now owns 2,403,685 shares of the company's stock worth $103,479,000 after buying an additional 346,317 shares during the period. Institutional investors and hedge funds own 98.45% of the company's stock.

Enovis Stock Up 4.0 %

Enovis stock opened at $36.92 on Wednesday. The stock's fifty day moving average is $43.76 and its two-hundred day moving average is $43.91. The stock has a market cap of $2.10 billion, a PE ratio of -16.86 and a beta of 2.05. Enovis Co. has a 1-year low of $35.14 and a 1-year high of $62.79. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.

Remove Ads

Enovis (NYSE:ENOV - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.06. The business had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. On average, sell-side analysts expect that Enovis Co. will post 2.79 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Needham & Company LLC decreased their price target on shares of Enovis from $65.00 to $64.00 and set a "buy" rating for the company in a research note on Thursday, February 27th.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Co. (NYSE:ENOV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.